| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Guanidine thiocyanate does not have a specific pharmacological target. It acts as a chaotropic agent and strong denaturant, disrupting cell membranes and denaturing proteins. It is used as a strong RNase inhibitor, protecting cellular transcripts from degradation during tissue extraction. Guanidine salts have demonstrated antiviral effects against poliovirus and other enteroviruses.
|
|---|---|
| ln Vitro |
In vitro, Guanidine thiocyanate is used for RNA isolation and protein solubilization. It is a key reagent used to denature proteins in cell lysis buffer. It is involved in the quantification of mRNA from hepatocytes and acts as a medium for blood sample lysis to maintain nucleic acid integrity. It is routinely used for DNA/RNA extraction protocols to prevent damage by degradative enzymes.
|
| ln Vivo |
In vivo, Guanidine salts have demonstrated antiviral effects against poliovirus and other enteroviruses in both in vitro and in vivo studies. Guanidine compounds have been shown to affect neuromuscular transmission by increasing the quantity of acetylcholine released from nerve endings, which enhances synaptic transmission.
|
| Enzyme Assay |
Guanidine thiocyanate's chaotropic and denaturing properties can be characterized in biochemical assays. The compound's ability to denature proteins and inhibit RNases is assessed using standard protein and nucleic acid assays. Its effectiveness in RNA isolation is evaluated by measuring RNA yield and integrity.
|
| Cell Assay |
In vitro cell experiments with Guanidine thiocyanate typically involve using the compound as a reagent for cell lysis and nucleic acid extraction. Cells are lysed in guanidine thiocyanate-containing buffers, and nucleic acids are isolated for downstream applications such as PCR and sequencing.
|
| Animal Protocol |
In vivo animal studies with Guanidine thiocyanate have been conducted to study its antiviral effects against poliovirus and other enteroviruses. The compound is typically administered via injection. Detailed protocols regarding dosage, treatment duration, and specific animal models are not extensively reported.
|
| ADME/Pharmacokinetics |
Guanidine thiocyanate is rapidly metabolized and cleared. As a chaotropic agent, it is used as a reagent rather than a therapeutic compound. Pharmacokinetic data specific to guanidine thiocyanate are limited in the available literature.
|
| Toxicity/Toxicokinetics |
Guanidine thiocyanate is considered safe for research use at typical concentrations. As a laboratory reagent, it is intended for research use only and not for human consumption. The compound should be handled under standard laboratory safety practices with appropriate precautions.
|
| References | |
| Additional Infomation |
Guanidine thiocyanate (GuSCN) is a chaotropic agent and strong denaturant used in research for protein degradation, DNA/RNA isolation, and purification. It is a key reagent for RNA isolation and can solubilize proteins. It acts as a strong RNase inhibitor, protecting transcripts from degradation.
|
| Molecular Formula |
C2H6N4S
|
|---|---|
| Molecular Weight |
118.16
|
| Exact Mass |
118.031
|
| CAS # |
593-84-0
|
| Related CAS # |
Guanidine hydrochloride;50-01-1
|
| PubChem CID |
65046
|
| Appearance |
White to off-white solid powder
|
| Density |
1.103 g/mL at 20 °C
|
| Boiling Point |
132.9ºC at 760 mmHg
|
| Melting Point |
120-122 °C(lit.)
|
| Flash Point |
34.2ºC
|
| Index of Refraction |
n20/D 1.482
|
| Source |
Endogenously produced metabolite
|
| LogP |
0.736
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
7
|
| Complexity |
57.6
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
SC#N.NC(N)=N
|
| InChi Key |
ZJYYHGLJYGJLLN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/CH5N3.CHNS/c2-1(3)4;2-1-3/h(H5,2,3,4);3H
|
| Chemical Name |
guanidine;thiocyanic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~846.31 mM)
H2O : ~100 mg/mL (~846.31 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (21.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (21.16 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (21.16 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.4631 mL | 42.3155 mL | 84.6310 mL | |
| 5 mM | 1.6926 mL | 8.4631 mL | 16.9262 mL | |
| 10 mM | 0.8463 mL | 4.2316 mL | 8.4631 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
